BPC-157: evidence, safety and FDA status

BPC-157 is marketed for tendon, joint and gut repair, but an animal finding, a symptom survey and a registered protocol have different evidentiary weight. FDA’s assessment found important identity and safety gaps ^[1]. A 2026 review’s three uncontrolled studies cover only part of the human record ^[6].

BPC-157 is a lab-made peptide first studied for stomach and tissue protection

BPC-157 is a synthetic peptide named "body protection compound." A 2025 review describes it as a naturally occurring gastric peptide, which is where the protective framing comes from ^[7]. The product sold today is made in a lab. It isn't a steroid and it isn't a hormone.

The name is less precise than it sounds. BPC-157 has no official drug name (no USAN). FDA says it has seen several salts and derivatives, including different active molecules, sold under the same "BPC-157" label ^[1]. FDA calls that a safety risk in its own right: a patient may get a different substance than the one written on the vial.

It also turns up in pill form. FDA notes that BPC-157 is marketed in the US as an ingredient in dietary-supplement capsules and tablets, with no supplement monograph that would define its quality ^[1].

BPC-157 is promoted for tendon, joint and gut healing, but nearly all of that comes from animals

Sellers and forums credit BPC-157 with faster healing of tendons, ligaments, muscle, bone and the gut lining. A 2025 sports-medicine systematic review searched the literature from 1993 to 2024 and found 36 usable studies: 35 preclinical and one clinical ^[7]. In rats and other animals, BPC-157 improved several measures of muscle, tendon, ligament and bone repair.

The same review found "no clinical safety data" in humans ^[7]. Animal repair models are a starting point for research, not proof that an injection will help your knee.

Human evidence extends beyond one review’s subtotal

Poolton’s 2026 systematic review included three uncontrolled reports totaling 30 analyzed participants and rated the evidence very low certainty ^[6]. It included knee-pain reports, a 12-woman bladder pilot and a two-person IV safety pilot. This is an inclusion subtotal rather than the entire historical human-exposure record.

For the knee report, 12 participants received BPC-157 alone and four surveyed participants also received full-length thymosin beta-4 ^[11]. Full-length thymosin beta-4 is not interchangeable with the fragment commonly called TB-500. Different reviews use different denominators; none turns this survey into a controlled trial.

A newer three-case nerve-injury report names BPC-157, TB-500 and ARA-290 together with a steroid and local anesthetics. It reports subjective improvement without a control or component attribution, and does not verify the molecular identity of the material called TB-500 ^[18]. It adds a limited human report, not a controlled comparison or a reliable response timetable; the TB-500 guide explains the fragment distinction.

The older FDA-reviewed enema material includes healthy-volunteer exposure as well as the ulcerative-colitis abstract. In the colitis trial, three active-arm and two placebo participants withdrew because of adverse events, mainly worsening colitis ^[1]. These events and the confidence interval must be considered alongside any favorable narrative. Route-specific observations do not establish the safety or effectiveness of commercial injections.

Current registrations include a recruiting hamstring-strain study and a not-yet-recruiting rotator-cuff study, without posted results ^{[13] [14]}. Registration describes a research plan; it does not itself establish every applicable authorization or a favorable outcome. The full efficacy review explains the study-level limitations.

An oral protocol does not settle the injection-versus-capsule question

The current oral-gummy record makes “no human oral study exists” too absolute. It does not establish human bioavailability, a reliable clinical benefit or superiority over an injection ^[12]. FDA’s route-specific pharmacokinetic gaps remain relevant ^[1]. The injected-versus-oral review separates formulation claims from comparative evidence.

Safety: what FDA flagged and what is simply unknown

FDA's stated concerns are immune reactions, impurities and mislabeled substances. Its safety-risks page says compounded BPC-157 may pose a risk of immunogenicity for some routes, may have problems with peptide-related impurities, and that FDA has "no, or only limited" safety information for the routes people propose ^[3].

FDA identified no human pharmacokinetic data for oral, subcutaneous, nasal or transdermal use within its assessment ^[1]. It described three FAERS injection reports, including injection-site reactions, shortness of breath and skin darkening, with uncertain causality. Three separate food/supplement complaints involved multiingredient products. These reporting systems are not interchangeable and do not supply an incidence rate.

Older data come from a different route. FDA's briefing summarizes early studies in which healthy volunteers received BPC-157 as an enema; headache and flatulence were the side effects reported most often ^[1]. That route is not how BPC-157 is sold today, so those reports say little about injections or capsules.

The reviewed sources do not establish a dependable long-term injection safety rate. The completed oral-gummy registry describes eight weeks of follow-up, but posts no results ^[12]. Duration listed in a protocol is not a safety finding. The BPC-157 safety review separates those gaps.

FDA approval and authorized investigation are different

FDA’s assessment identified no approved BPC-157 product in its regulatory review; this is an attributed assessment, not a new independent audit of every country ^[1]. Current 503A regulation does not list BPC-157, and the reviewed interim categories do not establish ordinary retail bulk eligibility ^{[16] [4]}.

Advisory recommendations are nonbinding. The peptide-policy notice under OIRA review is pending rather than issued policy with final terms ^[15]. Properly authorized investigation has separate requirements for manufacturing information, nonclinical evidence, oversight and eligibility ^[17]. A prescription or “research use only” label alone does not establish an exemption or authorization.

The FDA-status review and legal-access review explain the current records. Related MOTS-c and TB-500 research has its own identity and evidence questions; the compounds are not interchangeable.

BPC-157 is banned in sport at all times

WADA's 2026 Prohibited List names BPC-157 under S0, non-approved substances. S0 covers any drug not approved by a health authority for human use, and it is prohibited in and out of competition ^[10]. A 2025 sports-medicine review also urged clinicians to tell athletes about the ban ^[7].

Terms used on this page

• 503A bulks list: FDA's list of bulk ingredients that state-licensed pharmacies may use to compound drugs when no monograph or approved drug covers them.
• Category 2: FDA's group of nominated ingredients it says raise significant safety concerns; pharmacies compounding them risk FDA action.
• Pharmacy Compounding Advisory Committee (PCAC): outside experts who advise FDA on the bulks list. Their votes are not binding.
• Research use only (RUO): a label on chemicals sold for lab work. The label alone does not establish authorization, quality or safety for human treatment.